The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 17, 2019

Filed:

Oct. 22, 2015
Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Elisabetta Bianchi, Pomezia, IT;

Paul E. Carrington, South San Francisco, CA (US);

Qiaolin Deng, Edison, NJ (US);

Ravi Nargund, East Brunswick, NJ (US);

Federica Orvieto, Pomezia, IT;

Anandan Palani, Bridgewater, NJ (US);

Antonello Pessi, Rome, IT;

Thomas Joseph Tucker, North Wales, PA (US);

Chengwei Wu, Ambler, PA (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/605 (2006.01); A61K 38/26 (2006.01); A61K 38/28 (2006.01);
U.S. Cl.
CPC ...
A61K 38/28 (2013.01); A61K 38/26 (2013.01); C07K 14/605 (2013.01);
Abstract

Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.


Find Patent Forward Citations

Loading…